about
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialEstablishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines.Endometriosis Mimicking Soft-Tissue Neoplasms: A Potential Diagnostic Pitfall.Synovial Sarcoma: Advances in Diagnosis and Treatment Identification of New Biologic Targets to Improve Multimodal Therapy.High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth.Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting.Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma.Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.Cancer-testis antigens are predominantly expressed in uterine leiomyosarcoma compared with non-uterine leiomyosarcoma.Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers.The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype.MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1.
P2860
Q26769884-39EE68CB-EEE6-4BE8-BD30-82963E342F48Q37136357-226DB247-E163-4343-A5BF-D3B6917EFC1FQ38850816-B401F49A-9874-4D53-8A19-7707098A4811Q39126751-3C23825E-DB64-4667-B884-A21865752567Q39233440-53289845-C7AF-4138-9579-ABB10C04F2D7Q41026125-B97D4E09-A8AF-4B32-AED4-1B0CE04545A3Q42349256-B7950B3D-6729-4B9E-8974-A74CC0352CB2Q47132018-3B62BA23-DBC9-44E2-85F2-9ACE6BBCA71FQ47936113-F44CB201-1639-4C4F-ADAE-B9CD7550195EQ49335269-DED626C5-9074-4F08-89B3-5A5DF8554C92Q49859661-CD246273-04E0-4118-BC96-6AA8DA3776C4Q50420957-F6EA8E16-794C-4FB0-BF88-ED0B1096864FQ53083279-87D89B12-CC66-4780-A586-987BA9D3E64CQ54489272-489A00EC-7CA2-4E41-B499-E9B6C2D181D1
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
NY-ESO-1 (CTAG1B) expression in mesenchymal tumors.
@en
NY-ESO-1
@nl
type
label
NY-ESO-1 (CTAG1B) expression in mesenchymal tumors.
@en
NY-ESO-1
@nl
prefLabel
NY-ESO-1 (CTAG1B) expression in mesenchymal tumors.
@en
NY-ESO-1
@nl
P2093
P2860
P1433
P1476
NY-ESO-1 (CTAG1B) expression in mesenchymal tumors.
@en
P2093
Davis R Ingram
Dina C Lev
Inge H Briaire-de Bruijn
Makoto Endo
Marieke A de Graaff
Neeta Somaiah
Torsten O Nielsen
P2860
P2888
P304
P356
10.1038/MODPATHOL.2014.155
P577
2014-11-21T00:00:00Z